
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RQ3013
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Walvax Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RQ3013 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 31, 2022
Lead Product(s) : RQ3013
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Walvax Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RQ3013
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Walvax Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RQ3013 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : RQ3013
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Walvax Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Fudan University
Deal Size : Undisclosed
Deal Type : Collaboration
Towards an effective mRNA vaccine against 2019-nCoV
Details : A joint research team from Fudan University, Shanghai JiaoTong University, and RNACure Biopharma is currently working on a vaccine for COVID-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 07, 2020
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Fudan University
Deal Size : Undisclosed
Deal Type : Collaboration
